Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
128 hedge funds and large institutions have $555M invested in Five Prime Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 66 increasing their positions, 15 reducing their positions, and 28 closing their positions.
340% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 15
3% less capital invested
Capital invested by funds: $573M → $555M (-$17.8M)
7% less funds holding
Funds holding: 137 → 128 (-9)
21% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 28
55% less call options, than puts
Call options by funds: $1.22M | Put options by funds: $2.73M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$30.4M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$24.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.4M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$16.9M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$9.88M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.75M |
| 3 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$6.94M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.05M |
| 5 |
Morgan Stanley
New York
|
-$5.01M |
FPRX Hedge Fund Activity: Q1 2018 in Review
128 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q1 2018, worth a combined $555M — down 3.1% from $573M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of FPRX and 22 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 66 added.
The largest buyer was Wellington Management Group, adding an estimated $30.4M. The largest seller was Deerfield Management, exiting entirely with an estimated $9.88M sold.
- 128 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q1 2018, down from 137 in Q4 2017.
- Funds reported $555M of Five Prime Therapeutics, Inc. stock for Q1 2018, down 3.1% quarter-over-quarter.
- 22 funds opened new Five Prime Therapeutics, Inc. positions in Q1 2018 and 28 closed out, a net change of -6 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q1 2018 was Wellington Management Group, an estimated $30.4M added.
- The largest Five Prime Therapeutics, Inc. seller in Q1 2018 was Deerfield Management, an estimated $9.88M sold.
Based on aggregated 13F filings for Q1 2018.